Leading radiologists to highlight clinical examples demonstrating power of iCAD’s complete suite of ProFound AI Breast Health Solutions

NASHUA, N.H. – June 29, 2022 - iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that leading radiologists will highlight clinical examples demonstrating the power of ProFound AI® Ris... Continue reading

Leading experts, including distinguished researchers from the Karolinska Institutet and clinicians using it in daily practice, to discuss significant impact and value of technology

NASHUA, N.H. – June 7, 2022 - iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that its next webinar, titled “Risk Assessm... Continue reading

Stephen P. Sarno appointed as interim Chief Financial Officer to the Company, effective immediately

NASHUA, N.H., May 25, 2022 -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced the Board of Directors has approved the appointment of Stephen P. Sarno as interim Chief Financial Officer (CFO), effective immediately. Mr. Sarno will assist with the transition as Charles Carter departs the Company this month.

Research presented at the 2022 SBI/ACR Breast Imaging Symposium confirms ProFound AI significantly enhances radiologists’ screening performance

NASHUA, N.H., May 18, 2022 -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that new research supporting ProFound AI® for Digital Breast Tomosynthesis (DBT) will be presented at the Society of Breast Imaging (SBI/ACR) Breast Imaging Symposium, taking place May 16-19 in Sava... Continue reading

Using U.S. guidelines, ProFound AI Risk found 14% of women studied who had a negative screen had almost 20 times higher risk of developing breast cancer in the next year than the general risk population

iCAD recently announced that promising clinical research supporting ProFound AI® Risk for Digital Breast Tomosynthesis (DBT) – the world’s first clinical decision support tool that provides an accurate short-term breast cancer risk estimation based on age, breast density and mammographic fea... Continue reading

Using U.S. guidelines, ProFound AI Risk found 14% of women studied who had a negative screen had almost 20 times higher risk of developing breast cancer in the next year than the general risk population

NASHUA, N.H., May 16, 2022 -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that promising clinical research supporting ProFou... Continue reading

NASHUA, N.H., May 12, 2022 -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced the Company will present at the Spring Into Action – Best Ideas Virtual Investor Conference, which is being held virtually on May 16th – 20th, 2022.

Stacey Stevens, President and CEO of iCAD, Inc. will pre... Continue reading

Company to host conference call and webcast today at 4:30 PM ET

NASHUA, N.H. – May 11, 2022 – iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today reported its financial and operating results for the three months ended March 31, 2022.

Highlights:

Leading healthcare provider with 14 imaging centers in North Carolina identified ProFound AI as the premier solution in a competitive trial based on unique workflow benefits and multivendor flexibility

 NASHUA, N.H. – April 28, 2022 - iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that the next event in its “ProFound Insights, ProFound Impact” webinar series w... Continue reading

NASHUA, N.H. – April 27, 2022 –  iCAD®, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that it will release financial results for the first quarter ended March 31, 2022, after the market close, and host a conference call at 4:30 PM Eastern Time on Wednesday, May 11.

Wednesday, May 11th at 4:30 PM ET

Domestic:                    888-506-0062

Continue reading

Customers report continued workflow advantages and clinical superiority with iCAD’s suite of AI‐powered breast health solutions, compared to other available breast AI solutions

NASHUA, N.H. – April 26, 2022 ‐ iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, announced significant commercial momentum for ProFound AI®, driving attachment to the leading provider of 3D... Continue reading

Company expects preliminary estimated revenue to be .5 million

Timothy Norris Irish Appointed Chairman of the Board of Directors, Successor CFO search underway

NASHUA, N.H. – April 21, 2022 - iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader pro... Continue reading

First event to feature Kettering Health, a leading enterprise breast care provider with 14 breast centers across southwest Ohio

NASHUA, N.H. – April 19, 2022 - iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that it will launch a new webinar series, ProFound Insights, ProFound Impact, which will highl... Continue reading

Multiple leading institutions leverage the versatility of Xoft electronic brachytherapy (eBx) to increasingly treat multiple cancers

NASHUA, N.H. – April 5, 2021 – iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that additional patients have been treated under the international multi-center GLIOX trial and customers globally are continui... Continue reading

With 14 imaging locations in the Raleigh-Durham metropolitan area, also known as “the Triangle,” Wake Radiology offers a wide array of imaging exams in the outpatient setting, including both screening and diagnostic mammography. Renowned for state-of-the-art care, in August 2013 Wake Radiology began to upgrade to 3D mammography, or DBT, and now exclusively offers DBT at all 14 locations, all of which are designated as American College of Radiology Breast Imaging Centers of Excellence (BICOE).

“We pride o... Continue reading

The Story of Kettering Health

A leading faith based, not-for-profit hospital system in southwest Ohio, Kettering Health has been providing quality patient care and cancer screening at its world-class cancer centers for 48 years. The team at Kettering takes great pride in ensuring that its facilities are equipped with the latest in state-of-the-art technology that empowers their team to provide the best possible patient care.

“... Continue reading

World-leading breast cancer AI solutions featured for demonstration in iCAD booth

NASHUA, N.H., March 14, 2022 -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced it will be showcasing its portfolio of Breast AI solutions, including ProFound AI® for Digital Breast Tomosynthesis (DBT) in the iCAD booth (#4000) at the 2022 Healthcare Information and Management Sys... Continue reading

iCAD’s award winning portfolio of breast health solutions to be featured at inaugural Pink Paradigm Summit, uniting clinical and advocacy leadership

NASHUA, N.H., March 10, 2022 -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced it will be showcasing its portfolio of innovative breast health solutions at the National Consortium of Breast Centers (NCoBC) Annual Confere... Continue reading

NASHUA, N.H., March 9, 2022 -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced the Company will participate in the virtual 32nd Annual Oppenheimer Healthcare Conference, taking place March 15-17, 2022.

Stacey Stevens, President and CEO of iCAD, Inc. is scheduled to present on Thursday, March 17, 2022, at 8:00 a.m. EST. The webcast of this event can be vi... Continue reading

NVIDIA platform streamlines adoption, accelerates deployment of iCAD’s solutions in virtualized data centers

NASHUA, N.H. – March 2, 2022 –  iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that it is among the first to validate its AI solutions with the NVIDIA® AI Ente... Continue reading